NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Why?

The points are solid.

. NWBO has not mentioned the UCLA ATl-DC trials for years. Why not?
. The clinical trial registry does not list DCvax-L as a name it is known by even though copyrighted names are used in other cases of this nature
. The process for the ATL-DC used by UCLA (details below) is very different from that of DCVax-:L..
.... ATL-DC has every dose for a patient individually manufactured and used fresh. -L makes all in a single batch and freezes.
... Initial maturation time of ATL-DC is several days longer than DCvax-L
... Activation time is several hours longer. for ATL-DC than DCVax-L
.... Additional leukos may be performed as neeed to get more, fresh monocytes.,
. Several 3rd party reports have Prins saying it is NWBO's product.,

As opposed to this we have LL saying they are basically the same. What does "basically the same" mean either legally ownership wise or to the RAs.

Manufacturing differences per the Prins paper

6.5.3 Co-Culture of Dendritic Cells with Tumor Lysate
One day prior to each immunization, aliquots of the autologous dendritic cells will be thawed. A cell count will be obtained, viability assessed, purity evaluated, and an aliquot removed for sterility testing. The DC will then be centrifuged in preparation for loading with autologous tumor lysate.
...
DC pellet will be resuspended in 2 ml of tumor lysate in RPMI medium (noserum) and incubated for eighteen (18) to twenty-four (24) hours at 37 ºC and 5%CO2.

6.5.1 Preparation of Autologous Dendritic Cells (DC)
The flasks will be placed in the incubator for 7 to 10 days of culture.

I am sure since most here claim to understnd the science of -L they know well how different thus is from the -L manufacturing process and why this matter.